RS51331B - Upotreba pipamperona i antagonista d2-receptora ili serotoninsko/dopaminskih antagonista za lečenje psihotičkih poremećaja - Google Patents

Upotreba pipamperona i antagonista d2-receptora ili serotoninsko/dopaminskih antagonista za lečenje psihotičkih poremećaja

Info

Publication number
RS51331B
RS51331B RSP-2010/0323A RSP20100323A RS51331B RS 51331 B RS51331 B RS 51331B RS P20100323 A RSP20100323 A RS P20100323A RS 51331 B RS51331 B RS 51331B
Authority
RS
Serbia
Prior art keywords
pipamperone
treatment
compound
serotonin
day
Prior art date
Application number
RSP-2010/0323A
Other languages
English (en)
Serbian (sr)
Inventor
Erik Buntinx
Original Assignee
Pharmaneuroboost N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2451798A external-priority patent/CA2451798C/en
Priority claimed from US10/725,965 external-priority patent/US7884096B2/en
Priority claimed from EP03447279A external-priority patent/EP1547650A1/de
Priority claimed from US10/752,423 external-priority patent/US7855195B2/en
Priority claimed from CA 2461248 external-priority patent/CA2461248C/en
Priority claimed from EP04447066A external-priority patent/EP1576985A1/de
Priority claimed from US10/803,793 external-priority patent/US20050119249A1/en
Priority claimed from EP04025035A external-priority patent/EP1541197B8/de
Priority claimed from US10/984,683 external-priority patent/US20050203130A1/en
Priority claimed from CA 2487529 external-priority patent/CA2487529A1/en
Application filed by Pharmaneuroboost N.V. filed Critical Pharmaneuroboost N.V.
Publication of RS51331B publication Critical patent/RS51331B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RSP-2010/0323A 2003-12-02 2004-12-02 Upotreba pipamperona i antagonista d2-receptora ili serotoninsko/dopaminskih antagonista za lečenje psihotičkih poremećaja RS51331B (sr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
CA2451798A CA2451798C (en) 2003-12-02 2003-12-02 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US10/725,965 US7884096B2 (en) 2003-12-02 2003-12-02 Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP03447279A EP1547650A1 (de) 2003-12-02 2003-12-02 Verwendung von D4 und 5-HT2A Antagonisten, inverse Agonisten order partielle Agonisten
EP04447001 2004-01-05
US10/752,423 US7855195B2 (en) 2003-12-02 2004-01-06 Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA 2461248 CA2461248C (en) 2003-12-02 2004-03-18 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
EP04447066A EP1576985A1 (de) 2004-03-18 2004-03-18 Verwendung von Antagonisten, Inversagonisten oder partielle Agonisten des D4- und 5-HT2A Rezeptors
US10/803,793 US20050119249A1 (en) 2003-12-02 2004-03-18 Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP04025035A EP1541197B8 (de) 2003-12-02 2004-10-21 Verwendung von Pipamperon und einem SNDRI, SNRI oder SSRI zur Behandlung von Stimmungs- oder Angststörungen
JP2004349085A JP4571485B2 (ja) 2003-12-02 2004-11-04 Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
US10/984,683 US20050203130A1 (en) 2003-12-02 2004-11-09 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA 2487529 CA2487529A1 (en) 2003-12-02 2004-11-15 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists

Publications (1)

Publication Number Publication Date
RS51331B true RS51331B (sr) 2011-02-28

Family

ID=42134278

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2010/0323A RS51331B (sr) 2003-12-02 2004-12-02 Upotreba pipamperona i antagonista d2-receptora ili serotoninsko/dopaminskih antagonista za lečenje psihotičkih poremećaja

Country Status (8)

Country Link
AT (1) ATE464901T1 (de)
DE (1) DE602004026781D1 (de)
DK (1) DK1708790T3 (de)
ES (1) ES2343962T3 (de)
HR (1) HRP20100376T1 (de)
PT (1) PT1708790E (de)
RS (1) RS51331B (de)
SI (1) SI1708790T1 (de)

Also Published As

Publication number Publication date
PT1708790E (pt) 2010-07-09
ATE464901T1 (de) 2010-05-15
DE602004026781D1 (de) 2010-06-02
DK1708790T3 (da) 2010-06-21
SI1708790T1 (sl) 2010-09-30
HRP20100376T1 (hr) 2010-08-31
ES2343962T3 (es) 2010-08-13

Similar Documents

Publication Publication Date Title
EP1708790B1 (de) Verwendung von pipamperon und einem d2-rezeptor antagonisten oder einem serotonin/dopamin antagonisten zur behandlung von psychotischen störungen
US10682354B2 (en) Compositions and methods
US20050203130A1 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1541197B1 (de) Verwendung von Pipamperon und einem SNDRI, SNRI oder SSRI zur Behandlung von Stimmungs- oder Angststörungen
US6075028A (en) Method of treating Tourette's syndrome and related CNS disorders
US20050119249A1 (en) Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20120010242A1 (en) Low dose pipamperone in treating mood disorders
CA2601509A1 (en) Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
CN116940362A (zh) 在慢性ssri方案后使用苯二氮䓬增加对裸盖菇素的敏感性
US7884096B2 (en) Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP2236138A1 (de) Niedrigdosiertes Pipamperon zur Behandlung von Stimmungs- und Angstzustandsstörungen
EP1576985A1 (de) Verwendung von Antagonisten, Inversagonisten oder partielle Agonisten des D4- und 5-HT2A Rezeptors
EP1547650A1 (de) Verwendung von D4 und 5-HT2A Antagonisten, inverse Agonisten order partielle Agonisten
WO2010112530A1 (en) Pipamperone and a second agent in treating mood and anxiety disorders
RS51331B (sr) Upotreba pipamperona i antagonista d2-receptora ili serotoninsko/dopaminskih antagonista za lečenje psihotičkih poremećaja
WO2012154710A1 (en) Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with nicotine
US20080318926A1 (en) Methods of Treating Mood Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives
RU2508106C2 (ru) Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
US20250281498A1 (en) Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies
Class et al. Patent application title: USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Inventors: Michael Hayden (Herzliya, IL) Mahmoud Abdulhossein Pouladi (Singapore, SG) Assignees: PRILENIA NEUROTHERAPEUTICS LTD. NATIONAL UNIVERSITY OF SINGAPORE Agency For Science, Technology and Research
Maan Comparison of Methamphetamine and MDMA Extended Access Self-administration: Acquisition, Maintenance, and Response patterns
CA2451798C (en) Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
RU2508096C2 (ru) Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
WO2012072665A1 (en) Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
JP2002524508A (ja) 新規組成物